Thymosin Beta-4

Thymosin Beta-4 is described as binding monomeric G-actin, an interaction that can affect actin availability and cytoskeletal turnover. The supplied evidence associates this biology with cell migration, angiogenesis, inflammation-related signaling, and recruitment of endothelial cells, keratinocytes, and progenitor or stem cells at injured sites. It also reports hypotheses involving epicardial activation and cardiac-cell survival under low-oxygen conditions. Mechanistic observations alone do not demonstrate clinical benefit.

The supplied source describes randomized, vehicle-controlled ophthalmic studies of RGN-259, a 0.1 % Tbeta4 eye-drop formulation, in dry eye and neurotrophic keratopathy. It reports a 317-patient phase 2/3 dry-eye trial with significant improvements in corneal staining and ocular discomfort, published in peer-reviewed journals. It characterizes cardiac results, including a porcine myocardial-infarction model, as preclinical and reports effects on cell engraftment, infarct size, and recovery; it also says the human cardiac program did not produce an approved drug. Wound-healing and hair-growth findings are described as mainly rodent data. The source does not identify completed pivotal trials establishing systemic benefit outside the eye program, and it reports no controlled human trial data for TB-500 itself.